Oorja Bio raised $29.19 million to advance ORJ-001, a first-in-class peptide therapeutic entering Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis, a rare and progressive lung disease with no currently available disease-modifying therapies.
